Boyiadzis Status Report March, 13

8/22/2019 Boyiadzis Status Report March, 13

1/11

Section No Section name Chapter No Chapter Name PDF Doc Count per Richard

Typeset Pages

(excluding blank

pages)

Inputs R

Da

1 Adrenocortical cancer 7 10 29-Ja

2 Anal Cancer 4 8 29-Ja

3 Biliary: Gallbladder Cancer and

Cholangiocarcinoma6

11 29-Ja

4 Bladder Cancer 6 7 29-Ja

5 Brain cancer 11 17 29-Ja

6 BREAST CANCER 159 159 91 29-Ja

7 Carcinoma of Unknown Primacy 5 11 29-Ja

8 Cervical Cancer 16 18 29-Ja9 Colorectal Cancer 19 25 29-Ja

10 Endometrial Cancer 5 10 29-Ja

11 Esophageal Cancer 10 46 25 29-Ja

12 Gastric Cancer 9 34 22 29-Ja

13 Gestational Trophoblastic Neoplasia 10 25 12 29-Ja

14 Head and Neck cancer 25 105 59 29-Ja

15 Hepatocellular Carcinoma 4 8 4 29-Ja

16 HIV-Related Malignancies 14 30 14 29-Ja

17 Leukemia, Acute Lymphoblastic 45 45 22 29-Ja

18 LEUKEMIA, ACUTE MYELOGENOUS 28 28 14 29-Ja

19 Leukemia, chronic lymphocytic 13 13 15 29-Ja

20 Leukemia, Chronic Myelogeneous 14 14 9 29-Ja

21 Leukemia, hairy cell 9 9 7 29-Ja

22 Lung cancer 20 37 21 29-Ja

23 Lymphoma, Hodgkin 26 30 51 27 29-Ja

24 Lymphoma, Non Hodgkin 38 110 54 29-Ja

25 Melanoma 8 27 33 16 29-Ja

26 Mesothelioma6

2 11 6 29-Ja

27 Multiple Myeloma 83 83 41 29-Ja

28 Pancreatic Endocrine Tumours 8 32 23 15 29-Ja

29 Ovarian Cancer 26 44 94 47 29-Ja

30 PANCREATIC CANCER 19 19 12 29-Ja

31 Pheochronocytoma 5 3 10 5 29-Ja

32 Prostate cancer 7 21 43 19 29-Ja

33 Renal Cell cancer 15 54 36 29-Ja

34 Sarcomas 31 18 152 81 29-Ja35 Testicular Cancer 27 27 14 29-Ja

36 THYMIC MALIGNANCIES 5 10 4 29-Ja

37 Thyroid Cancer 7 1 25 12 29-Ja

38 Vaginal Cancer 7 7 6 29-Ja

39 Prophylaxis and Treatment of

Chemotherapy-Induced Nausea and

Vomiting (CINV)

15 15 8 29-Ja

40 Drug Preparation and

Administration

328 328 143 29-Ja

41 Guidelines for Chemotherapy

Dosage Adjustment

43 43 32 29-Ja

42 Antineoplastic Drugs: Preventing

and Managing Extravasation

42 42 16 29-Ja

43 Indications for Growth Factors in the

Hematology-Oncology Setting

37 37 18 29-Ja

44 Indications for Biophosphonates in a 7 17 11 29 Ja

105

50

65

1 Oncology

Printer date:

Copy editing :

Indexing: Kathi Unger (US)

Proof reading:

Sample sent on: 27- feb- 13

Sample Approved on : 4-March- 13

printer test sent on

printer test approved on : 19 April, 13

Printer : Quad Graphics/Versailles.

CIP: To come from MH


2/11

48 Catheter-Related Bloodstream

Infections: Management and

Prevention

5 8 5 29-Jan-1

49 Venous Catherer-Related

Thrombosis

11 11 4 29-Jan-1

50 Complications and Follow Up After

Hematopoietic Cell Transplantation

38 38 18 29-Jan-1

51 Radiation Complications 51 51 24 29-Jan-1

52 Cancer Pain: Assessment andManagement

19 32 17 29-Jan-1

53 Hospice Care and End of Life Issues 12 12 5 29-Jan-1

54 Cancer Screening 3 5 3 29-Jan-1

55 Genetics of Common Inherited

Cancer Syndromes

12 12 8 29-Jan-1

56 von Willebrand Disease 40 40 26 29-Jan-1

57 Hemophilia 45 45 24 29-Jan-1

58 The Hypercoagulable State 11 22 12 29-Jan-1

59 Heparin-Induced Thrombocytopenia 20 20 17 29-Jan-1

60 AUTOIMMUNE HEMOLYTIC ANEMIA 34 34 35 29-Jan-1

61 SICKLE CELL DISEASE: ACUTE

COMPLICATIONS

30 30 26 29-Jan-1

62 Aplastic Anemia 15 15 8 29-Jan-1

63 THROMBOTIC THROMBOCYTOPENIC

PURPURA / HEMOLYTIC UREMIC

SYNDROME (TTP/HUS)

10 10 8 29-Jan-1

64 IDIOPATHIC THROMBOCYTOPENIC

PURPURA

20 20 14 29-Jan-1

65 Hemochromatosis 11 11 6 29-Jan-1

66 Myeloproliferative Neoplasms

(MPN)

81 81 40 29-Jan-1

67 MYELODYSPLASTIC SYNDROMES 34 34 17 29-Jan-1

Total 398 1606 2633 1432

Selected

Hematologic

Diseases

3

creen ng


3/11

Revised pages actually

sent on

Final Printer Files due to

McGraw-Hill

Final Printer Files to

mcgraw-hill actually sent onRemarks

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-1319-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-1319-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-1319-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13


4/11

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13

19-Jul-13


5/11

EDITOR PREFERENCE SHEET

EDITOR NAME SCHEDULE SHARED ON COMMENTS

Michael Boyiadzis 7 feb, 13

thank you for your e-mail.

Looking forward working with

you.


6/11

MODE OF DELIVERY SHIPPING ADDRESS EMAIL ADDRESS

e.proofs NA [email protected]
mailto:[email protected]:[email protected]


7/11

McGraw-Hill Production Manager: Richard Ruzycka

Project Development Editor: Harriet Lebowitz

Proofs Distribution: Editor + McGraw-Hill

Arts Proof Distribution: NA

Compositor - ThomsonXML: no

Printer: Quad Graphics/Versailles.

Printer Date: 19th July 2013

Milestone Original Scheduled

dates

Actual Dates R

Material to Thomson 29-Jan-13 29-Jan-13

Cast Off /Estimate to McGraw-Hill HE 20-Feb-13 2-Mar-13

Thomson to send Sample Chapter to McGraw-Hill HE 27-Feb-13 27-Feb-13

app

4

Thomson to send Printer Test 28-Mar-13 28-Mar-13

Copyediting completed 10-Apr-13

First Page proofs to Editor/MGH for Batch 1 - chapters 1 to 20 25-Mar-13 25-Mar-13

First Page proofs to Editor/MGH for Batch 2 -chapters 21 to 40 15-Apr-13 16-Apr-13

First Page proofs to Editor/MGH for Batch 3 -chapters 41 to 67 6-May-13 7-May-13

Return of First Page Proof corrections from Editors to TD 10-Jun-13

Marked revised proofs and index (By TD) proofs to McGraw-Hill 12-Jul-13

Final Print Files to McGraw-Hill HE 19-Jul-13

Editors will get 3 weeks to review each batch

Schedule for Boyiadzis Project


8/11

Copy editor Richard Adin

Chapter Due Date Actual Date

Sample (chapter 17) 20-Feb 18-Feb

chapters 6, 18-21, 27, 30, 35,

38, 39 23-Feb

chapters 1-5, 7-11, 15, and 40 2-Mar

Chapter 1 to 20 9-Mar

Chapter 21 to 40 30-MarChapter 41 to 67 10-Apr

Cast Off 31-Aug

PO pages Amount

496 2000 6,000.00$

Additional 496A 1000 3,000.00$

Invoice no Batch Chapters Pages Amount

213017 1(chapters 6, 18-21, 27, 30, 35,38, 39) 461 1,383.00$

213019 2 Chapters 1-5, 7-11, 15 and 40) 600 1,800.00$

213023 3

Chapters 12- 14, 16, 41-43, 45-

47, 49-51, 53, 55 560 1,680.00$

213025 4

Chapter- 22, 26, 31, 36, 56,

57, 59, 60, and 61 319 957.00$

213026 5 Chapter 37, 62-67 220 660.00$

213030 6 Chapter 23, 25, 28, 32, 33 208 624.00$

213033 7 Chapter 24, 29 and 34 354 1,062.00$

213035 8 Chapter 44, 48, 52, 54 and 58 86 258.00$

213036 9 Chapter 15 and 16 49 147.00$

213038 10 Chapter 9 Additional pages 52 156.00$

2909 8,727.00$


9/11

Proof reader- Heather

Chapter 17 given to PR on 28 FebDue to PR Back form PR

chapter 1 to 20 10-Mar 20-Mar

Chapter 21 to 40 31-Mar 10-Apr

Chapter 41 to 67 14-Apr 1-May

Invoice No. Pages Amount

Batch 1 1069 322 $563

Batch 2 1076 572 $1,001

Batch 1b 1077 80 $140

Batch 3 1088 515 $901 includes 47 additonal pages for

Total 1489 $2,605


10/11

Chapter 9, 15 and 16


11/11

Batch Chapter No Page No

24 11025 33

28 23

29 94

32 43

33 54

34 152

44 17

48 8

52 32

54 5

58 22

2

3

Boyiadzis Status Report March, 13

Documents

Transcript of Boyiadzis Status Report March, 13